1. Bell JE, Ironside JW. Neuropathology of spongiform encephalophaties in humans. Br Med Bull, 1993; 49: 738-77.

2. Brown P, Bradley R. 1755 and all that: a historical primer of transmissible spongiform encephalopathy. BMJ 1998; 317: 1688-92.

3. Brown P, Gibbs CJ, Rodgers-Johnson P, Asher DM, Sulima MP, Bacote A, et al. Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann Neurol 1994; 35: 513-29.

4. DeArmond SJ. Overview of the transmissible spongiform encephalophaties: prion protein disorders. Br Med Bull 1993; 49: 725-37.

5. DeArmond SJ, Prusiner SB. Etiology and pathogenesis of prion diseases. Am J Pathol 1995; 146: 785-811.

6. Haywood AM. Transmissible spongiform encephalophaties. N Engl J Med 1997; 337: 1821-8.

7. Head MW, Ironside JW. Review: Creutzfeldt–Jakob disease: prion protein type, disease phenotype and agent strain. Neuropathol Appl Neurobiol 2012; 38: 296-310.

8. Imran M, Mahmood S. An overview of human prion diseases. Virology Journal [revista en internet] 2011 [consultado 28 de diciembre de 2016]; 8: 559 [9 pantallas]. Disponible en: http://www.virologyj.com/content/8/1/559.

9. Ironside JW. Prion diseases in man. J Pathol 1998; 186: 227-34.

10. Lantos PL. From slow virus to prion: a review of transmissible spongiform encephalophaties. Histophatology 1992; 20: 1-11.

11. Prusiner SB, Hsiao KK. Human prion diseases. Ann Neurol 1994; 35: 385-95.

12. Prusiner SB. The prion diseases. Brain Pathol 1998; 8: 499-513.

13. Richardson EP, Masters CL. The nosology of Creutzfeldt-Jakob disease and conditions related to the accumulation of PrP^CJD in the nervous system. Brain Pathol 1995; 5: 33-41.

14. van der Valk P. Prion diseases: what will be next?. J Clin Pathol 1998; 51: 265-9.

15. Wadsworth JDF, Collinge J. Update on human prion disease. Biochim Biophys Acta 2007; 1772 (6): 598-609.

16. Collinge J, Sidle KC, Meads J, Ironside J, Hill AF. Molecular analysis of prion strain variation and the aetiology of “new variant” CJD. Nature 1996; 383: 685-90.

17. Hernández A, Céspedes G, González J. Enfermedades priónicas en humanos. Gac Méd Caracas 2002; 110 (1): 9-18.

18. Prusiner SB. Molecular biology of prion disease. Science 1991; 252: 1515-22.

19. Tateishi J. Prion diseases. Microbiol Immunol 1995; 39: 923-8.

20. Brown P. The risk of bovine spongiform encephalopathy (“mad cow disease”) to human health. JAMA 1997; 278: 1008-11.

21. Brown P, Will RG, Bradley R, Asher DM, Detwiler L. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: background, evolution, and current concerns. Emerg Infect Dis [revista en internet] 2001 jan-feb [consultado 25 de febrero de 2001]; 7 (1): [13 pantallas]. Disponible en: http://www.cdc.gov/ncidoc/eid/vol7no1/brown.htm.

22. Hernández A, Céspedes G, Romero S. Encefalopatía espongiforme bovina o “enfermedad de las vacas locas”. Gac Méd Caracas 2002; 110 (2): 151-65.

23. Prusiner SB. Prion diseases and the BSE crisis. Science 1997; 278: 245-50.

24. Sánchez-Juan P, Cousens SN, Will RG, van Duijn CM. Source of variant Creutzfeldt-Jakob disease outside United Kingdom. Emerg Infect Dis 2007; 13 (8): 1166-9.

25. Brown P, Cathala F, Raubertas RF, Gajdusek DC, Castaigne P. The epidemiology of Creutzfeldt-Jakob disease: conclusion of a 15-year investigation in France and review of the world literature. Neurology 1987; 37: 895-904.

26. Will RG. Epidemiology of Creutzfeldt-Jakob disease. Br Med Bull 1993; 49: 960-70.

27. World Health Organization. Public health issues and clinical and neurological characteristics of the new variant of Creutzfeldt-Jakob disease and other human and animal transmissible spongiform encephalopathies: memorandum from two WHO meetings. Bull World Health Organ 1996; 74: 453-63.

28. Kretzchmar HA, Ironside JW, DeArmond SJ, Tateishi J. Diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Arch Neurol 1996; 53: 913-20.

29. Will R, Zeidler M. Diagnosing Creutzfeldt-Jakob disease [letter]. BMJ 1996; 313: 833-4.

30. Kenney K, Brechtel C, Takahashi H, Kurohara K, Anderson P, Gibbs CJ. An enzyme-linked immunosorbent assay to quantify 14-3-3 proteins in the cerebrospinal fluid of suspected Creutzfeldt-Jakob disease patients. Ann Neurol 2000; 48: 395-8.

31. Lemstra AW, van Meegen MT, Vreyling JP, Meijerink PHS, Jansen GH, Bulk S, et al. 14-3-3 testing in diagnosing Creutzfeldt-Jakob disease. A prospective study in 112 patients. Neurology 2000; 55: 514-6.

32. Wiltfang J, Otto M, Baxter HC, Bodemer M, Steinacker P, Bahn E, et al. Isoform pattern of 14-3-3 proteins in the cerebrospinal fluid of patients with Creuztfeldt-Jakob disease. J Neurochem 1999; 73: 2485-90.

33. Zeidler M. 14-3-3 cerebrospinal fluid protein and Creutzfeldt-Jakob disease [letter]. Ann Neurol 2000; 47: 683-4.

34. Atarashi R, Sano K, Satoh K, Nishida N. Real-time quaking-induced conversion. A highly sensitive assay for prion detection. Prion 2011; 5 (3): 150-3.

35. McGuire L, Peden A, Orrú C, Wilham J, Appleford N, Mallinson G, et al. RT-QuIC analysis of cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease. Ann Neurol 2012; 72 (2): 278-85.

36. Van Everbroeck B, Pals P, Dziedzic T, Dom R, Godfraind C, Sciot R, et al. Retrospective study of Creutzfeldt-Jakob disease in Belgium: neuropathological findings. Acta Neuropathol 2000; 99: 358-64.

37. Tateishi J, Kitamoto T. Developments in diagnosis for prion diseases. Br Med Bull 1993; 49: 971-9.

38. Yokoyama T. The immunodetection of the abnormal isoform of prion protein. Histochem J 1999; 31: 209-12.

39. Aguzzi A, Weissmann C. A suspicious signature. Nature 1996; 383: 666-7.

40. Castellani RJ, Parchi P, Madoff L, Gambetti P, McKeever P. Biopsy diagnosis of Creutzfeldt-Jakob disease by Western blot: a case report. Hum Pathol 1997; 28: 623-6.

41. Schulz-Schaeffer WJ, Tschöke S, Kranefuss N, Dröse W, Hause-Reitner D, Giese A, et al. The paraffin-embedded tissue blot detects PrP^Sc early in the incubation time in prion disease. Am J Pathol 2000; 156: 51-6.

42. Boussin F, Jaegly A, Deslys JP, Dormont D. A simple and rapid method for sequencing the entire coding region of the human prion protein (PrP) gene. J Neurosci Methods 1994; 54: 103-7.

43. Collinge J, Harding AE, Owen F, Poulter M, Lofthouse R, Boughey AM, et al. Diagnosis of Gerstmann-Sträussler syndrome in familial dementia with prion protein gene analysis. Lancet 1989; july 1: 15-7.

44. Petraroli R, Vaccari G, Pocchiari M. A rapid and efficient method for the detection of point mutations of the human prion protein gene (PRNP) by direct sequencing. J Neurosci Methods 2000; 99: 59-63.

45. Zimmermann K, Turecek PL, Schwarz HP. Genotyping of the prion protein gene at codon 129. Acta Neuropathol 1999; 97: 355-8.

46. Caraballo AJ. Creutzfeldt-Jakob disease in Venezuela: a case report. Arq Neuro-Psiquiat (Sâo Paulo) 1991; 49: 218-21.

47. Faoro A, Filomena MV, de Pernía E, Borges J. Importancia del EEG en el diagnóstico de la Enfermedad de Jakob-Creutzfeldt. A propósito de dos casos. Rev Ven Neurol Neurocir 1987; 1: 17-20.

48. Hernández A, Céspedes G, González A, Alvárez A, Lara C, Soto A, y col. Enfermedad de Creutzfeldt-Jakob en Venezuela: informe de 10 casos y revisión de la literatura. Rev Inst Nac Hig “Rafael Rangel” 1999; 30: 14-20.

49. Hernández A, Céspedes G, Larrea F, Querales J, Romero G, López N. Encefalopatías espongiformes transmisibles o enfermedades priónicas. Revisión general y casuística venezolana. Organización Panamericana de la Salud y Facultad de Medicina de la Universidad Central de Venezuela: Caracas, 2002.

50. Méndez O, Luzardo G, Molina O, Cardozo J. Enfermedad de Creutzfeldt-Jakob. Reporte de 2 casos. Invest Clín 1995; 36: 23-30.

51. Postalian K, Mariño C, López J, Amundaray G. Enfermedad de Creutzfeldt-Jakob: a propósito de un caso con proteína 14-3-3 y resonancia magnética por difusión pesada. Centro Médico 2004; 49 (2): 100-5.

52. Caruzo G, Díaz F, Bohórquez M, Rodríguez L, Gambetti P, Molina O, y col. Encefalopatía priónica familiar. En: XLIII Jornadas Venezolanas de Anatomía Patológica. San Cristobal: Sociedad Venezolana de Anatomía Patológica; 1999. p.17.

53. Hernández A, Céspedes G. Medidas de bioseguridad para el manejo clínico y de laboratorio de pacientes con enfermedades priónicas. Gac Méd Caracas 2002; 110 (3): 318-27.

54. Gambetti P, Kong Q, Zou W, Parchi P, Chen SG. Sporadic and familial CJD: classification and characterisation. Br Med Bull 2003; 66: 213-39.

55. Tateishi J, Kitamoto T. Inherited prion diseases and transmission to rodents. Brain Pathol 1995; 5: 53-9.

56. Gambetti P, Petersen R, Monari L, Tabaton M, Autilio-Gambetti L, Cortelli P, et al. Fatal familial insomnia and the widening spectrum of prion diseases. Br Med Bull 1993; 49: 980-94.

57. Ghetti B, Dlouhy SR, Giaccone G, Bugiani O, Frangione B, Farlow MR, et al. Gerstmann-Sträussler-Scheinker disease and the Indiana Kindred. Brain Pathol 1995; 5: 61-75.

58. Cervenáková L, Goldfarb LG, Garruto R, Lee H-S, Gajdusek DC, Brown P. Phenotype-genotype studies in kuru: implications for new variant Creutzfeldt-Jakob disease. Proc Natl Acad Sci USA 1998; 95: 13239-41.

59. McLean CA, Ironside JW, Alpers MP, Brown PW, Cervenáková L, Anderson RMcD, et al. Comparative neuropathology of Kuru with the new variant of Creutzfeldt-Jakob disease: evidence for strain if agent predominating over genotype of host. Brain Pathol 1998; 8: 429-37.

60. Aguzzi A, Zhu C. Five questions on prion diseases. PLoS Pathogens [revista en internet] 2012 [consultado 28 de diciembre de 2016]; 8 (5): [4 pantallas]. Disponible en: www.plospathogens.org.

61. Brown P, Preece M, Brandel J-P, Sato T, McShane L, Zerr I, et al. Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology 2000; 55: 1075-81.

62. Almond J, Pattison J. Human BSE. Nature 1997; 389: 437-8.

63. Ashraf H. BSE inquiry uncovers “a peculiarly British disaster”. Lancet 2000; 356: 1579-80.

64. Balter M. Tracking the human fallout from “mad cow disease”. Science 2000; 289: 1452-4.

65. Collee JG, Bradley R. BSE: a decade on-part 2. Lancet 1997; 349: 715-21.

66. Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347: 921-5.

67. Will RG, Zeidler M, Stewart GE, Macleod MA, Ironside JW, Cousens SN, et al. Diagnosis of new variant Creutzfeldt-Jakob disease. Ann Neurol 2000; 47: 575-82.

68. Zeidler M, Johnstone EC, Bamber RWK, Dickens CM, Fisher CJ, Francis AF, et al. New variant Creutzfeldt-Jakob disease: psychiatric features. Lancet 1997; 350: 908-10.

69. Zeidler M, Stewart GE, Barraclough CR, Bateman DE, Bates D, Burn DJ, et al. New variant Creutzfeldt-Jakob disease: neurological features and diagnostic test. Lancet 1997; 350: 903-7.

70. Streichenberger N, Jordan D, Verejan I, Souchier C, Philippeau F, Gros E, et al. The first case of new variant Creutzfeldt-Jakob disease in France: clinical data and neuropathological findings. Acta Neuropathol 2000; 99: 704-8.

71. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, Suttie A, et al. Transmissions to mice indicate that “new variant” CJD is caused by BSE agent. Nature 1997; 389: 498-501.